Oslo University Hospital, Rikshospitalet is one of the four main campuses of Oslo University Hospital in Oslo, Norway. It was an independent hospital, Rigshospitalet, later spelled Rikshospitalet, from 1826 to 2009, when it merged with other university hospitals in Oslo.

There are 585 beds in Oslo Universitetssykehus HF, Rikshospitalet.

During the past decade, Oslo Universitetssykehus HF, Rikshospitalet conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 15 clinical trials were completed, i.e. on average, 39.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 11 clinical trials were completed. i.e. 68.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oslo Universitetssykehus HF, Rikshospitalet" #1 sponsor was "Boehringer Ingelheim" with 12 trials, followed by "Oslo University Hospital" with 9 trials sponsored, "Baxalta now part of Shire" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oslo Universitetssykehus HF, Rikshospitalet" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Medtronic" with 2 trials as a collaborator, "Norwegian Health Association" with 2 trials as a collaborator and "Oslo University Hospital" with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Oslo Universitetssykehus HF, Rikshospitalet" are "Hemophilia A" (5 trials), "Lung Diseases, Interstitial" (4 trials), "Atrial Fibrillation" (3 trials), "Multiple Myeloma" (3 trials) and "Ankylosing Spondylitis" (2 trials). Many other conditions were trialed in "Oslo Universitetssykehus HF, Rikshospitalet" in a lesser frequency.

Most popular intervention types in "Oslo Universitetssykehus HF, Rikshospitalet" are "Drug" (44 trials), "Device" (9 trials), "Other" (7 trials), "Procedure" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Nintedanib" (3 trials), "BI 1015550" (2 trials), "Bortezomib" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oslo Universitetssykehus HF, Rikshospitalet" are 66 trials for "All" genders, 4 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Oslo Universitetssykehus HF, Rikshospitalet". undefined are not yet recruiting, 12 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in Oslo Universitetssykehus HF, Rikshospitalet, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Oslo Universitetssykehus HF, Rikshospitalet, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 10 trials that are defined as “Not Applicable".